A Phase 2 interventional study of Nilotinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 21st largest by enrollment, is one of 4 that started in 2011, is one of 25 in phase 2, and was the 26th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 26th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2011, is one of 19 in phase 2, and was the 41st registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia (CML-CP).
This was a multicenter, open-label, single-arm, phase 2 study of nilotinib as a frontline treatment for patients with Ph+ CMLCP. All patients received oral nilotinib 300 mg twice daily for a planned treatment duration of 24 months or until early discontinuation.
The primary efficacy end point was the cumulative rate of Major Molecular Response (MMR) in all participants by 12 months. Secondary efficacy end points included the rate of Complete Cytogenic Response (CCyR) at 6 and 12 months; cumulative rates of MMR up to 24 months; time to and durability of MMR; and cumulative rate of Complete Haematologic Response (CHR) by 12 months.
Patient evaluations, including hematologic assessments, were conducted every 15 days during the first 3 months, monthly until month 12, and then every 3 months until the end of the study (24 months). All efficacy analyses were performed in the intent-to treat population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered orally at a dose of 300 mg twice daily for 24 months
Drug: Nilotinib
administered orally at a dose of 300 mg twice daily for 24 months
Also known as: Tasigna, AMN107
Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months
Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.
Time frame: 12 months
Percentage of Participants Who Achieved Major Molecular Response (MMR) up to 24 Months
Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.
Time frame: 3, 6, 9, 15, 18, 21 and 24 months
Percentage of Participants With Complete Cytogenetic Response (CCyR) at Month 6 and 12
CCyR rate is identified as the rate of patients who had 0% of Ph+ metaphase.
Time frame: Month 6 and 12
Percentage of Participants With Complete Hematologic Response (CHR) at Month 3, 6, 9, 12, 18 and 24
A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved: WBC \<10 x 109/L, thrombocyte \<450 x 109/L, myelocyte + metamyelocyte \<%5 in blood, no sign of blast and promyelocyte in blood, basophil \<%5, and no sign of extramedullary involvement.
Time frame: Month 3, 6, 9, 12, 18 and 24
Time to Major Molecular Response (MMR)
Time to MMR is defined as the time period from the date of first dose intake until the first documented MMR.
Time frame: 24 months
Duration of Major Molecular Response (MMR)
MMR duration is defined as the time from the date of first documented MMR to the first time of the lost MMR, progression or death.
Time frame: 24 months
A total of 112 participants were enrolled into the study from the 15 sites in Turkey.
| Milestone | Nilotinib |
|---|---|
| Started | 112 |
| Completed | 92 |
| Not completed | 20 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Patient not compliant with the protocol | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Death | 2 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Adverse event | 8 |
| Withdrew: Progression of disease | 3 |
| Withdrew: Hospitalization | 1 |
Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.
| Participants | Nilotinib |
|---|---|
| Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months | 74 |
Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.
| Participants | Nilotinib |
|---|---|
| 3 months | 28 |
| 6 months | 57 |
| 9 months | 67 |
| 15 months | 84 |
| 18 months | 92 |
| 21 months | 93 |
| 24 months | 93 |
CCyR rate is identified as the rate of patients who had 0% of Ph+ metaphase.
| Participants | Nilotinib |
|---|---|
| Month 6 | 89 |
| Month 12 | 84 |
A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved: WBC \<10 x 109/L, thrombocyte \<450 x 109/L, myelocyte + metamyelocyte \<%5 in blood, no sign of blast and promyelocyte in blood, basophil \<%5, and no sign of extramedullary involvement.
| Participants | Nilotinib |
|---|---|
| Month 3 | 104 |
| Month 6 | 102 |
| Month 9 | 100 |
| Month 12 | 96 |
| Month 18 | 93 |
| Month 24 | 92 |
Time to MMR is defined as the time period from the date of first dose intake until the first documented MMR.
| days | Nilotinib |
|---|---|
| Time to Major Molecular Response (MMR) | 252.38 ± 153.22 |
MMR duration is defined as the time from the date of first documented MMR to the first time of the lost MMR, progression or death.
| days | Nilotinib |
|---|---|
| Duration of Major Molecular Response (MMR) | 91 ± 4.22 |
Collected over Adverse events were collected from the start of the treatment to end of the treatment i.e 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | 2/112 (1.8%) | 43/112 (38.4%) | 90/112 (80.4%) |
| Event | Nilotinib |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 4/112 |
| Chest PainCardiac disorders | 3/112 |
| Arteriogram coronaryInvestigations | 3/112 |
| NeutropeniaBlood and lymphatic system disorders | 2/112 |
| Acute myocardial infarctionCardiac disorders | 2/112 |
| Abdominal painGastrointestinal disorders | 2/112 |
| Lipase increasedInvestigations | 2/112 |
| Acute leukaemiaBlood and lymphatic system disorders | 1/112 |
| Angina unstableCardiac disorders | 1/112 |
| BradycardiaCardiac disorders | 1/112 |
| Event | Nilotinib |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 19/112 |
| HyperbilirubinaemiaHepatobiliary disorders | 17/112 |
| PruritusSkin and subcutaneous tissue disorders | 16/112 |
| InfluenzaRespiratory, thoracic and mediastinal disorders | 13/112 |
| RashSkin and subcutaneous tissue disorders | 13/112 |
| Alanine aminotransferase increasedInvestigations | 12/112 |
| Blood triglycerides increasedInvestigations | 11/112 |
| HypercholesterolaemiaHepatobiliary disorders | 11/112 |
| Blood alkaline phosphatase increasedInvestigations | 10/112 |
| LeukopeniaBlood and lymphatic system disorders | 10/112 |
| Age, Continuous(years) | Nilotinib |
|---|---|
| Median | 47 (19 to 78) |
| Sex: Female, Male(Participants) | Nilotinib |
|---|---|
| Female | 49 |
| Male | 63 |
| Race and Ethnicity Not Collected(Participants) | Nilotinib |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jan 2011 to primary completion in Aug 2019, 102 months.
Results were first posted in Sep 2020, 1 year 1 month after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 102 months is above that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →